2-ethyl-5-methoxy-4-[(4-nitrophenyl)methoxy]benzaldehyde | 1350809-55-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-ethyl-5-methoxy-4-[(4-nitrophenyl)methoxy]benzaldehyde
• CAS: 1350809-55-0
• 化学式: C₁₇H₁₇NO₅
• 分子量: 315.326
• InChiKey: IEUUHVXLCSPNMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.56
• 重原子数：
  23.0
• 可旋转键数：
  7.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  78.67
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  2-ethyl-5-methoxy-4-[(4-nitrophenyl)methoxy]benzaldehyde 、 5-nitro-1-benzofuran-2-carbohydrazide hydrochloride 在 sodium acetate 作用下， 以 甲苯 、 乙二醇二甲醚 为溶剂， 反应 32.0h， 以64%的产率得到N-[(E)-[2-ethyl-5-methoxy-4-[(4-nitrophenyl)methoxy]phenyl]methylideneamino]-5-nitro-1-benzofuran-2-carboxamide
  参考文献：
  名称：

  A new method for induced fit docking (genius) and its application to virtual screening of novel HCV NS3-4A protease inhibitors

  摘要：

  Hepatitis C virus (HCV) is an etiologic agent of chronic liver disease, and approximately 170 million people worldwide are infected with the virus. HCV NS3-4A serine protease is essential for the replication of this virus, and thus has been investigated as an attractive target for anti-HCV drugs. In this study, we developed our new induced-fit docking program (GENIUS), and applied it to the discovery of a new class of NS3-4A protease inhibitors (IC50 = 1-10 mu M including high selectivity index). The new inhibitors thus identified were modified, based on the docking models, and revealed preliminary structure-activity relationships. Moreover, the GENIUS in silico screening performance was validated by using an enrichment factor. We believe our designed scaffold could contribute to the improvement of HCV chemotherapy. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.09.023
• 作为产物：
  描述：

  对硝基溴化苄 在 四(三苯基膦)钯 、 氢气 、 sodium carbonate 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 32.0h， 生成 2-ethyl-5-methoxy-4-[(4-nitrophenyl)methoxy]benzaldehyde
  参考文献：
  名称：

  A new method for induced fit docking (genius) and its application to virtual screening of novel HCV NS3-4A protease inhibitors

  摘要：

  Hepatitis C virus (HCV) is an etiologic agent of chronic liver disease, and approximately 170 million people worldwide are infected with the virus. HCV NS3-4A serine protease is essential for the replication of this virus, and thus has been investigated as an attractive target for anti-HCV drugs. In this study, we developed our new induced-fit docking program (GENIUS), and applied it to the discovery of a new class of NS3-4A protease inhibitors (IC50 = 1-10 mu M including high selectivity index). The new inhibitors thus identified were modified, based on the docking models, and revealed preliminary structure-activity relationships. Moreover, the GENIUS in silico screening performance was validated by using an enrichment factor. We believe our designed scaffold could contribute to the improvement of HCV chemotherapy. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.09.023